889.6500 6.35 (0.72%)
NSE May 21, 2025 15:31 PM
Volume: 1.7M
 

Karvy
Valuation and Risks: We reduce our Revenues for FY21E / FY22E by 1.6% / 2.5% due to downgrade across revenue segments with the exception of US and EU.
Zydus Lifesciences Ltd.'s price crossed above 50Day SMA today
More from Zydus Lifesciences Ltd.
All Rapid Results
Recommended